-
On April 21, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that HS-20093 for injection (risvutatug rezetecan) has been designated as a Breakthrough Therapy candidate for the treatment of patients with advanced castration-resistant prostate ca...Read more »
-
Recently, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) announced that Encorafenib has been provisionally approved for priority review. It will be used in combination with cetuximab and the FOLFOX chemotherapy regimen as a first-line treatment for...Read more »
-
When the words “pancreatic cancer” appear on a diagnostic report—especially when accompanied by “25 liver metastases”—countless families have been plunged into despair. This disease, known as the “king of cancers,” once diagnosed with multiple metastases, often...Read more »
-
Recently, Bayer announced that China’s National Medical Products Administration (NMPA) has approved the novel targeted drug sevabertinib for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who harbor HER2 (ERBB2) activating mutat...Read more »
-
Dear International Patients, When you or your loved ones are battling cancer and seeking gentler, more effective treatment options, we would like to introduce you to a revolutionary oncology technology — Ultrasound Tissue Fragmentation Therapy. This advanced treatment has been successfully implem...Read more »
-
When cancer casts a shadow over life, every treatment choice carries profound implications for both the quality and dignity of that life. For patients who are of advanced age, have poor cardiopulmonary function, cannot tolerate surgery or anesthesia, or seek a gentler way to fight the tumor, the ...Read more »
-
On March 31, 2026, the Center for Drug Evaluation of China’s National Medical Products Administration delivered exciting news: GFH375, developed by GenFleet Therapeutics, has been officially included as a “Breakthrough Therapy” candidate for the treatment of patients with metastatic pancreatic ca...Read more »
-
For many elderly cancer patients and their families, a diagnosis often comes with despair. Especially when facing the “king of cancers”—pancreatic cancer—the excruciating pain and inability to eat often strip patients of their dignity, leaving their loved ones in profound distress. To...Read more »
-
On March 24, 2024, the Center for Drug Evaluation of China’s National Medical Products Administration announced that the innovative drug Teclistamab is proposed to be designated as a breakthrough therapy for the monotherapy treatment of adult patients with relapsed or refractory multiple my...Read more »
-
Recently, the National Medical Products Administration (NMPA) approved a new indication for the antibody-drug conjugate (ADC) Disitamab vedotin for the treatment of adult breast cancer patients with unresectable or metastatic HER2-low expression (IHC 1+ or IHC 2+/ISH-) and liver metastases, who h...Read more »
-
On March 10, 2026, the innovative B7-H3-targeting antibody-drug conjugate (ADC) YL201 for injection, developed by MediLink Therapeutics, was granted Breakthrough Therapy Designation by the Center for Drug Evaluation of China’s National Medical Products Administration. The designated indicat...Read more »
-
Recently, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration officially approved the KSD-101 injection, developed by Kousai, to enter clinical trials. This marks not only the first original dendritic cell vaccine (DC vaccine) in China to receive FDA IND app...Read more »
Cooperative medical institution of
Beijing Cancer Hospital